6月26日 - ** Incyte（INCY.O）股价上涨5.1%，至113.02美元
** 这家制药公司表示，欧洲药品管理局（EMA）的关键专家委员会建议批准其用于治疗炎症性皮肤病的药膏Opzelura，用于治疗患有中度特应性皮炎（一种常见的湿疹类型）的成人患者
** 该公司称，对于使用标准药膏疗效不佳的中度湿疹患者而言，Opzelura有望成为欧盟首款此类不含类固醇的皮肤软膏
** 称晚期临床数据表明，该药膏在第8周即可改善湿疹症状，并能帮助将病情控制至第24周，且耐受性良好
** 欧盟委员会将对该建议进行审议；若获批，这将是Opzelura继非节段性白癜风之后在欧盟获批的第二个适应症——INCY
** 计入本次交易，INCY今年以来累计上涨14.1%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.